Mechanical thrombectomy in basilar artery occlusion: influence of reperfusion on clinical outcome and impact of the first-line strategy (ADAPT vs stent retriever)

Benjamin Gory, MD, PhD;1 Mikael Mazighi, MD, PhD;2–5 Raphael Blanc, MD, MSc;2 Julien Labreuche, BST;6 Michel Piotin, MD, PhD;2 Francis Turjman, MD, PhD;7 and Bertrand Lapergue, MD, PhD;8 on behalf of the Endovascular Treatment in Ischemic Stroke (ETIS) Research Investigators

1Department of Diagnostic and Interventional Neuroradiology, INSERM U947, University Hospital of Nancy, University of Lorraine, Nancy; 2Department of Interventional Neuroradiology, Rothschild Foundation, Paris; 3DHU NeuroVasc Sorbonne Paris Cité; 4Paris Diderot University (Paris 7), Paris; 5Laboratory of Vascular Translational Science, INSERM U1148, Paris; 6Department of Biostatistics, EA2694-Santé publique: épidémiologie et qualité des soins, Lille University, Lille; 7Department of Interventional Neuroradiology, Hospices Civils de Lyon; and 8Department of Neurology, Stroke Center, Foch Hospital, Université de Versailles Saint-Quentin-en-Yvelines, Suresnes, France

OBJECTIVE Several randomized trials have been focused on patients with anterior circulation stroke, whereas few data on posterior circulation stroke are available. Thus, new mechanical thrombectomy (MT) strategies, including a direct-aspiration first-pass technique (ADAPT), remain to be evaluated in basilar artery occlusion (BAO) patients. The authors here assessed the influence of reperfusion on outcome in BAO patients and examined whether ADAPT improves the reperfusion rate compared with stent retriever devices.

METHODS Three comprehensive stroke centers prospectively collected individual data from BAO patients treated with MT. Baseline characteristics as well as radiographic and clinical outcomes were compared between the 2 MT strategies. The primary outcome measure was the rate of successful reperfusion, defined as a modified Thrombolysis in Cerebral Infarction (mTICI) grade of 2b–3. Favorable outcome was defined as a 90-day modified Rankin Scale score of 0–2.

RESULTS Among the 100 adult patients included in the study, 46 were treated with first-line ADAPT (median age 61 years, IQR 53–71 years; stent-retriever rescue therapy was secondarily used in 12 [26.1%]) and 54 were treated with a primary stent retriever (median age 67 years, IQR 53–78 years). There was no difference in baseline characteristics between the 2 treatment groups, except for the rate of diabetes (19.6% vs 5.7%, respectively, p = 0.035). Successful reperfusion was achieved in 79% of the overall study sample. Overall, the rate of favorable outcome was 36.8% and 90-day all-cause mortality was 44.2%. Successful reperfusion positively impacted favorable outcome (OR 4.57, 95% CI 1.24–16.87, p = 0.023). A nonsignificant trend toward a higher successful reperfusion rate (unadjusted OR 2.56, 95% CI 0.90–7.29, p = 0.071) and a significantly higher rate of complete reperfusion (mTICI grade 3; unadjusted OR 2.59, 95% CI 1.14–5.86, p = 0.021) was found in the ADAPT group. The procedure duration was also significantly lower in the ADAPT group (median 45 minutes, IQR 34 to 62 minutes vs 56 minutes, IQR 40 to 90 minutes; p = 0.05), as was the rate of periprocedural complications (4.3% vs 25.9%, p = 0.003). Symptomatic intracranial hemorrhage (0.0% vs 4.0%, p = 0.51) and 90-day all-cause mortality (46.7% vs 42.0%, p = 0.65) were similar in the 2 groups.

CONCLUSIONS Among BAO patients, successful reperfusion is a strong predictor of a 90-day favorable outcome, and the choice of ADAPT as the first-line strategy achieves a significantly higher rate of complete reperfusion with a shorter procedure duration.

https://thejns.org/doi/abs/10.3171/2017.7.JNS171043

KEY WORDS acute stroke; ADAPT; stent retriever; thrombectomy; basilar artery occlusion; aspiration; reperfusion; vascular disorders
M
echanical thrombectomy (MT) has been validated through 6 international randomized controlled trials in patients with acute ischemic stroke caused by occlusion of the arteries of the proximal anterior circulation.2,12 However, patients with basilar artery occlusion (BAO) were excluded from 5 of these trials, and only a few such patients were included in the THROMBIE (THR0bectomy des Artères Cérébrales) trial.2 In patients with BAO, prognosis remains severe with a high mortality rate, especially in the absence of early reperfusion.27 Pending the results of randomized trials,17,31 there is, to date, no consensus regarding the management of these patients, especially in view of results from the BASICS (Basilic Artery International Cooperation Study) registry reporting no benefit from the intraarterial approach compared with medical treatment.25 It is noteworthy that no modern MT devices improving reperfusion and clinical outcomes22,24 were used in the BASICS.

Recent data on BAO patients treated with stent retrievers reveal that clinical outcomes with a wide range of functional independence can be achieved.11 The latest treatment, a direct-aspiration first-pass technique (ADAPT), involves first-line aspiration to remove the thrombus through a large-bore aspiration catheter.30 These large catheters are important tools for MT of a large-vessel occlusion allowing high rates of reperfusion mainly reported in the anterior circulation (Gory B, et al: A direct aspiration first pass technique [ADAPT] for acute ischemic stroke therapy: a systematic review and meta-analysis; submitted, 2017).16

We, therefore, assessed the influence of reperfusion on outcome in BAO patients and, by pooling prospective individual data from 3 comprehensive stroke centers, examined whether ADAPT improves the reperfusion rate compared with stent retriever devices.

Methods

Study Design and Population

In this study, we conducted a retrospective analysis of our prospectively collected, large-vessel occlusion stroke, endovascular database to identify patients presenting with BAO between March 2010 and October 2016 at 3 comprehensive stroke centers (Endovascular Treatment in Ischemic Stroke [ETIS] registry). Detailed materials and methods have been reported elsewhere.16 The local ethics committee approved this research protocol.

There was no prespecified protocol for the treatment of BAO strokes at our centers during the study period. The decision to treat or not to treat any given patient with BAO on presentation was left to the attending neuroendovascular specialist’s discretion in agreement with the stroke team caring for the patient and the patient’s family.

Endovascular Procedure

The aim of the MT procedure was to achieve successful reperfusion (modified Thrombolysis In Cerebral Ischemia [mTICI] grade ≥ 2b) of the territory of the occluded vessel as quickly as possible.33 The first-line device was chosen at the neurointerventionist’s discretion, either a stent retriever or a large-bore aspiration catheter (ADAPT; Fig. 1), with the possibility of switching to another strategy in the case of reperfusion failure (mTICI grade < 2b) with the first approach.

Eligibility and Data Collection

Inclusion criteria were as follows: 1) acute stroke symptoms with no upper age or National Institutes of Health Stroke Scale (NIHSS) score limit; 2) BAO confirmed on angiography with time from the “last known normal” patient status to treatment of less than 24 hours; 3) reperfusion using stent retrievers or primary aspiration with large-bore catheters (ADAPT); and 4) thrombectomy performed either as the primary treatment or as an add-on to intravenous thrombolysis with recombinant tissue plasminogen activator. Intravenous thrombolysis was administered in eligible patients in accordance with current management guidelines. No specific exclusion criteria were applied. The institutional review board at each center approved the study.

The following variables were collected: age; sex; medical history including main vascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, and current smoking); initial stroke severity as expressed by the admission NIHSS score; initial imaging modality at admission and the Alberta Stroke Programme Early CT Score (ASPECTS); prior use of intravenous thrombolysis; and type of MT devices. Procedure was monitored according to procedure-related complications, degree of reperfusion assessed per the mTICI scale,26 time from symptom onset to successful reperfusion, and conventional angiography at the end of thrombectomy. The mTICI grade was scored as follows: 0 (no recanalization), no perfusion or antegrade flow beyond the occlusion site; 1 (minimal recanalization), contrast medium passes the area of occlusion but fails to opacify the entire cerebral bed distal to the obstruction during the angiographic run; 2 (partial recanalization), 2a: partial filling, < 50% of territory visualized, 2b: partial filling, ≥ 50% of territory visualized; and 3 (complete recanalization), total reperfusion with normal filling. Clinical outcome was assessed using the modified Rankin Scale (mRS) score, as were intracranial hemorrhage at 24 hours on cerebral imaging (MRI or CT) and mortality. The mRS score was assigned as follows: 0, no symptoms; 1, no clinically relevant disability; 2, slight disability (able to look after own affairs without assistance but not to a full extent); 3, moderate disability (requires some help but able to walk unassisted); 4, moderately severe disability (unable to attend to own bodily needs or to walk without assistance); 5, severe disability (requires constant nursing care); and 6, dead. Intracranial hemorrhage was classified as hemorrhagic infarction or parenchymal hemorrhage.13

Outcome Measures

The primary efficacy outcome measure was successful reperfusion, defined as mTICI grade 2b–3 at the end...
of the procedure, as assessed by the treating physician. Secondary efficacy outcomes included complete reperfusion (mTICI grade 3), change in NIHSS score at 24 hours, favorable outcome (defined as 90-day mRS score 0–2), and all-cause mortality at 90-days. Safety outcomes of interest included procedural complications, intracranial hemorrhage complication on brain imaging at 24 hours, and symptomatic intracranial hemorrhage (defined as any hemorrhage on follow-up imaging associated with an increase of ≥ 4 points in the NIHSS score according to the European Co-operative Acute Stroke Study-II [ECASS-II] criteria).\(^\text{13}\)

**Statistical Analysis**

Quantitative variables are expressed as medians (interquartile range), and categorical variables are expressed as numbers (percentage). Normality of distributions was assessed using histograms and the Shapiro-Wilk test.

Bivariate comparisons between the 2 study groups (ADAPT vs stent retriever) were made using the chi-square test (or Fisher’s exact test when the expected cell frequency was < 5) for categorical variables, the Student t-test for Gaussian continuous variables, and the Mann-Whitney U-test for non-Gaussian continuous and ordinal categorical variables, as appropriate. Differences (ADAPT vs stent retriever group) in binary efficacy outcomes (successful reperfusion, complete reperfusion, favorable outcome, and 90-day mortality) between the 2 groups were expressed as odds ratios, and the difference in the 24-hour NIHSS change was expressed as a standardized difference calculated on rank-transformed data using nonparametric ANCOVA including the admission NIHSS score as a covariable;\(^\text{5}\) the 95% confidence interval of the standardized difference was calculated using the bootstrap method (2000 bootstrap samples).\(^\text{8}\) Comparisons between efficacy outcomes were further adjusted for prespecified confounding factors (age and admission NIHSS) and baseline differences (at \(p < 0.10\) in bivariate analyses) by using logistic regression models for binary outcomes and non-parametric ANCOVA for the change in the NIHSS score. Because of missing data on outcomes (favorable outcome and mortality, 5%; change in NIHSS, 21%) and confounding factors (5%), we performed sensitivity analyses using a multiple imputation approach to handle missing values.
Missing data were imputed under the missing-at-random assumption by using the regression-switching approach (chained equation with m = 10 imputations obtained using R statistical software version 3.03). Imputation procedure was performed under the missing-at-random assumption using all baseline characteristics and the study outcomes with a predictive mean matching method for continuous variables and multinomial or binary logistic regression model for categorical variables. Estimates obtained in the different imputed data sets were combined using Rubin's rules. Finally, among the overall patient population, we studied the impact of successful reperfusion on a favorable outcome by using logistic regression analysis before and after adjustment for first-line treatment approach, age, and admission NIHSS score. Statistical testing was done at the 2-tailed α level of 0.05. Data were analyzed using SAS software version 9.3 (SAS Institute).

Results

Baseline Characteristics

During the study period, 100 adults with BAO were treated with MT at the 3 participating centers, with a median delay of 315 minutes (IQR 225 to 382 minutes; Fig. 2) from symptom onset to groin puncture. Patients’ baseline characteristics are described for the overall study sample and according to the first-line endovascular approach in Table 1. A total of 46 patients were treated with primary aspiration, and the remaining 54 patients were treated with stent retrievers. Overall, the median age was 65 years (IQR 53 to 77 years), 61% of the patients were men, and the median pretreatment NIHSS score was 16 (IQR 11 to 29). Forty-five patients received intravenous thrombolysis prior to endovascular treatment within a median delay of 170 minutes from symptom onset. Except for a lower rate of diabetes in the patients treated with a stent retriever (5.7% vs 19.6%, p = 0.035), there were no significant differences in baseline characteristics between the 2 treatment groups. Although the difference did not reach the significance level, the delay from symptom onset to groin puncture was longer in the ADAPT group than in the stent retriever group.

In the ADAPT group, the overall device cost was $229,479 ($175,484 for primary aspiration and $53,995 dollars for stent-retriever rescue therapy). In the stent retriever group, the overall device cost was $249,727 dollars ($242,978 for primary stent retriever thrombectomy and $6749 for rescue devices).

Procedural Characteristics and Complications

Table 2 shows the procedural characteristics overall and according to the first-line endovascular approach. Most of the patients were treated under general anesthesia (84.0%), with no difference according to the first-line approach utilized. Primary aspiration was performed mostly with a 5MAX ACE catheter (65.2%), and primary stent retriever thrombectomy was performed mostly with the Solitaire device (77.8%). Rescue treatment after the first-line strategy was more often necessary in the ADAPT group than in the stent retriever group (26.1% vs 3.7%, p = 0.001).

Procedural complications occurred in 16% of patients (95% CI 9.4%–24.7%) and were significantly more frequent in the stent retriever group than in the ADAPT group (25.9% vs 4.3%, p = 0.003). Embolization to a new territory was the most frequent procedural complication,
occurring in 11% of cases overall. Hemorrhagic complications at 24 hours occurred in 15.7% of patients (95% CI 8.8%–25.0%) with no significant difference between first-line endovascular approaches (12.8% vs 18.0%, p = 0.51).

Angiographic and Clinical Efficacy Outcomes

Figure 3 shows the distribution of reperfusion grades at the end of procedure and 90-day clinical outcome, according to treatment group. Overall, successful reperfusion was achieved in 79.0% of the patients (95% CI 69.7%–86.5%). Secondary outcome rates were 42.0% (95% CI 32.2%–52.3%) for complete reperfusion, 36.8% (95% CI 27.1%–47.4%) for a favorable outcome, and 44.2% for 90-day all-cause mortality (95% CI 34.0%–54.8%). The median 24-hour decrease in the NIHSS score was 3 points (IQR 10 to 4 points; Table 3).

Compared with the stent retriever group, the ADAPT group showed a nonsignificant trend toward a higher successful reperfusion rate, with an unadjusted OR of 2.56 (95% CI 0.90–7.29, p = 0.071; Tables 3 and 4). The median time from groin puncture to successful reperfusion was lower in the ADAPT group than in the stent retriever group (45 minutes [IQR 34 to 62 minutes] vs 56 minutes [IQR 40 to 90 minutes], p = 0.050). Regarding other secondary efficacy outcomes, only a significantly higher rate of complete reperfusion was found in favor of the first-line aspiration approach (unadjusted OR 2.59, 95% CI 1.14–5.86, p = 0.021). Similar results were found after adjustment for center, age, admission NIHSS score, diabetes, and time from symptom onset to groin puncture, using multiple imputations to handle missing outcomes and covariates.

Successful Reperfusion and Favorable Outcome

In the 2 groups pooled, patients with successful reperfusion had a favorable outcome (32 patients [43.2%]) more often than the patients without successful reperfusion (14.3%; unadjusted OR 2.59, 95% CI 1.14–5.86, p = 0.021). The impact of successful reperfusion on favorable outcome was unchanged after adjustment for the first-line endovascular approach, age, and admission NIHSS score (adjusted OR 5.64, 95% CI 1.32–24.06).

Discussion

This analysis of pooled individual data shows that in BAO patients, successful reperfusion is a strong predictor of a favorable 90-day outcome and that the choice of ADAPT as the first-line endovascular strategy improves the rate of complete reperfusion and reduces procedure duration compared with the stent retriever technique. In addition, embolization to a new territory occurred more frequently in patients treated with a stent retriever.

This study is one of the largest multicenter series dealing with outcomes of modern MT in patients with angiographically proven BAO. Our analysis confirms that high reperfusion rates can be achieved with the use of modern
MT in BAO. Similar reperfusion rates were observed in the Endovascular Stroke Treatment (ENDOSTROKE) study including 148 BAO patients (stent retriever treatment in 84%) and in the stent retriever thrombectomy meta-analysis including 312 subjects. A higher reperfusion rate was recently reported in a small series including 38 patients (89%), 7 of whom had been treated only with intraarterial thrombolysis. According to our results, successful reperfusion improved the clinical outcome and ADAPT led to a higher complete reperfusion rate, which appears to be a better predictor of a favorable outcome than mTICI grade 2b. To date, a direct comparison according to the type of first-line endovascular approach in BAO patients has been used in only 2 small, retrospective single-center studies including, respectively, 31 (18 aspirations vs 13 stent retrievers) and 33 (20 aspirations vs 13 stent retrievers) patients. In both studies, ADAPT seemed to allow more rapid and complete recanalization than stent retriever thrombectomy. A larger, retrospective multicenter series compared the results of stent retriever treatment and aspiration thrombectomy as primary approaches; unfortunately, however, only 48 BAO patients were included in that study.

The exact relationship between reperfusion and outcome is not fully resolved in BAO patients. In the ENDOSTROKE study, reperfusion per se did not predict a good outcome, whereas a strong effect of reperfusion on the rate of a good outcome was demonstrated in another series, as we found in our current study. To date, 2 randomized clinical trials have compared stent retrievers and ADAPT thrombectomy for large-vessel occlusions of the anterior circulation (Contact Aspiration vs Stent Retriever for Successful Revascularization [ASTER] study, NCT02523261; Comparison of Aspiration vs Stent Retriever as first-line approach [COMPASS], NCT02466893), and ADAPT did not result in better reperfusion in the ASTER trial. No data are available in the setting of posterior circulation strokes. Improving the technology of aspiration catheters

### TABLE 2. Procedural characteristics and complications in 100 patients treated for BAO

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Overall</th>
<th>ADAPT</th>
<th>Stent Retriever</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>100</td>
<td>46</td>
<td>54</td>
<td>0.73</td>
</tr>
<tr>
<td>General anesthesia</td>
<td>84/100 (84.0)</td>
<td>38/46 (82.6)</td>
<td>46/54 (85.2)</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>First-line endovascular device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aspiration device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5MAX ACE</td>
<td>—</td>
<td>30/46 (65.2)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5MAX</td>
<td>—</td>
<td>8/46 (17.4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Other aspiration device*</td>
<td>—</td>
<td>8/46 (17.4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Stent retriever device</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solitaire</td>
<td>—</td>
<td>—</td>
<td>42/54 (77.8)</td>
<td>—</td>
</tr>
<tr>
<td>Trevo</td>
<td>—</td>
<td>—</td>
<td>7/54 (13.0)</td>
<td>—</td>
</tr>
<tr>
<td>Other stent retriever device†</td>
<td>—</td>
<td>—</td>
<td>5/54 (9.3)</td>
<td>—</td>
</tr>
<tr>
<td>Rescue therapy‡</td>
<td>14/100 (14.0)</td>
<td>12/46 (26.1)</td>
<td>2/54 (3.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>No. of total passes§</td>
<td>2 (1–3)</td>
<td>2 (1–3)</td>
<td>2 (1–3)</td>
<td>0.43</td>
</tr>
<tr>
<td>Acute antiplatelet therapy¶</td>
<td>13/99 (13.1)</td>
<td>5/46 (10.9)</td>
<td>8/53 (15.1)</td>
<td>0.53</td>
</tr>
<tr>
<td>Permanent stenting**</td>
<td>18/100 (18.0)</td>
<td>5/46 (10.9)</td>
<td>13/54 (24.1)</td>
<td>0.087</td>
</tr>
<tr>
<td>Intracranial angioplasty</td>
<td>21/100 (21.0)</td>
<td>11/46 (23.9)</td>
<td>10/54 (18.5)</td>
<td>0.51</td>
</tr>
<tr>
<td>Any procedural complication</td>
<td>16/100 (16.0)</td>
<td>2/46 (4.3)</td>
<td>14/54 (25.9)</td>
<td>0.003</td>
</tr>
<tr>
<td>New-territory embolic event</td>
<td>11/100 (11.0)</td>
<td>1/46 (2.2)</td>
<td>10/54 (18.5)</td>
<td>—</td>
</tr>
<tr>
<td>Vessel perforation</td>
<td>4/100 (4.0)</td>
<td>1/46 (2.2)</td>
<td>3/54 (5.6)</td>
<td>—</td>
</tr>
<tr>
<td>Arterial dissection</td>
<td>1/100 (1.0)</td>
<td>0/46 (0.0)</td>
<td>1/54 (1.9)</td>
<td>—</td>
</tr>
<tr>
<td>Any hemorrhagic complication</td>
<td>14/89 (15.7)</td>
<td>5/39 (12.8)</td>
<td>9/50 (18.0)</td>
<td>0.51</td>
</tr>
<tr>
<td>sICH</td>
<td>2/89 (2.2)</td>
<td>0/39 (0.0)</td>
<td>2/50 (4.0)</td>
<td>—</td>
</tr>
<tr>
<td>SAH</td>
<td>1/89 (1.1)</td>
<td>0/39 (0.0)</td>
<td>1/50 (2.0)</td>
<td>—</td>
</tr>
<tr>
<td>PH1</td>
<td>3/89 (3.4)</td>
<td>2/39 (5.1)</td>
<td>1/50 (2.0)</td>
<td>—</td>
</tr>
<tr>
<td>PH2</td>
<td>1/89 (1.1)</td>
<td>0/39 (0.0)</td>
<td>1/50 (2.0)</td>
<td>—</td>
</tr>
</tbody>
</table>

PH1 = parenchymal hematoma type 1; PH2 = parenchymal hematoma type 2; SAH = subarachnoid hemorrhage; sICH = symptomatic intracranial hemorrhage. Values are expressed as the number/total number (%) or median (interquartile range).

* Catheter 3MAX (1 patient), catheter ACE64 (2 patients), Catheter ARC (3 patients), Catheter Navien5F (1 patient), and not indicated (1 patient).
† Stent retriever Capture (3 patients), Revive (2 patients).
‡ Rescue therapy was defined as the use of another endovascular strategy after failure of the first-line treatment (mTICI grade 0–2a).
§ One missing value.
¶ Acute antiplatelet therapy was defined as the administration of at least 1 antiplatelet medication.
** Permanent stenting is defined as placement of a stent in the setting of underlying atherosclerotic stenosis > 70% (NASCET).
may lead to better reperfusion and, subsequently, to better outcomes.

In our study, the rate of favorable outcomes was similar to that in previously published studies, although overall mortality was somewhat higher. However, a direct comparison is hampered by differences in individual clinical and imaging characteristics. Indeed, patients undergoing MRI prior to reperfusion have significantly better clinical outcomes. In our study, MRI-guided selection was performed in 73% of cases. Although a trend to-
ward a better clinical outcome at 24 hours and 90 days was noted after ADAPT, the technique’s clinical benefit was not demonstrated in our study, at least in part because of our small sample size, despite a higher successful reperfusion rate. A second explanation is that the relationship between clinical outcome and recanalization is weaker than that described in the anterior circulation, as reported in the ENDOSTROKE study. In the latter study, the authors demonstrated that the use of a stent retriever (the reference device in the present study) was associated with higher recanalization rates than non–stent-retriever devices.

Procedural complications occurred more frequently after stent retriever thrombectomy, especially in terms of new-territory embolic events. A low rate of complications due to embolization in a new territory has been previously described, although no difference was observed in the ASTER trial (2.7% vs 3.7%). The systematic use of a balloon catheter probably explains the low rate of embolic complications after stent retriever thrombectomy in ASTER, as previously reported. However, the benefit of balloon catheter use for BAO thrombectomy is not yet established. Intracranial aspiration with proximal flow arrest by a balloon guiding catheter may also reduce the rate of embolic complications. Other safety parameters were similar between the aspiration and stent retriever groups in our study.

**Study Limitations**

The present study has several limitations. First, our findings are derived from observational nonrandomized analyses, which are subject to well-known limitations. We cannot rule out possible confounding effects by measured or unmeasured variables. Although our study included one of the largest reported series of stroke patients with BAO treated using MT, no formal study sample size was calculated. Thus, we cannot exclude that some differences may have been overlooked due to a lack of statistical power. In a posterior power calculation, we calculated the smallest significant between-group difference (expressed as effect size using the odds ratio) that our study sample size allowed us to detect with 80% power, assuming an incidence of outcome of 20% and 60% in the control group (stent retriever). Under these assumptions, only large differences could be detected with an OR of 3.38 and 3.66, respectively (or 0.30 and 0.27 for protective effects). Second, imaging outcomes were not evaluated by an independent committee across the 3 databases, even for the primary end point. Furthermore, the validity of mTICI grade has not been clearly approved for the posterior circulation, and mTICI has failed to achieve substantial interobserver agreement in posterior circulation stroke. In addition, various sizes of aspiration catheters and stent retrievers were used. For these reasons, the present findings can only be considered as hypothesis generating.

**Conclusions**

This study indicates that in BAO patients, successful reperfusion is a strong predictor of a 90-day favorable outcome and that ADAPT as the first-line strategy improves the rate of complete reperfusion and reduces procedure duration. These findings have potentially important implications for the current standards of practice in MT. Indeed, ADAPT may be a good option as a first-line approach in the setting of acute BAO since rapid and complete reperfusion is the major objective of acute ischemic stroke therapy. On the basis of these results, a randomized clinical trial directly comparing the 2 MT strategies is warranted.

**Acknowledgments**

We thank Mary Osborne-Pellegrin for help in editing the final draft of the manuscript.

**Appendix**

**Endovascular Treatment In Ischemic Stroke (ETIS) Research Investigators**

Jean-Pierre Decroix, Foch Hospital; Adrien Wang, Foch

---

**TABLE 4. Comparison of angiographic and clinical efficacy outcomes between 2 endovascular approaches after handling missing values**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>First-Line Endovascular Approach</th>
<th>Stent Retriever</th>
<th>Effect Size</th>
<th>Unadjusted Value (95% CI)</th>
<th>p</th>
<th>Adjusted‡ Value (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>ADAPT</td>
<td>46</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reperfusion at end of procedure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mTICI 2b–3*</td>
<td></td>
<td>87.0%</td>
<td></td>
<td>Odds ratio 2.56 (0.90 to 7.29)</td>
<td>0.071</td>
<td>2.34 (0.80 to 6.82)</td>
<td>0.12</td>
</tr>
<tr>
<td>mTICI 3</td>
<td></td>
<td>54.4%</td>
<td></td>
<td>Odds ratio 2.59 (1.14 to 5.86)</td>
<td>0.021</td>
<td>2.51 (1.07 to 5.84)</td>
<td>0.034</td>
</tr>
<tr>
<td>Clinical outcome</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in NIHSS score at 24 hrs</td>
<td></td>
<td>−1 (−7 to 14)</td>
<td></td>
<td>SD† 0.22 (−0.05 to 0.73)</td>
<td>0.31</td>
<td>0.17 (−0.12 to 0.66)</td>
<td>0.42</td>
</tr>
<tr>
<td>90-day favorable outcome: mRS score 0–2</td>
<td></td>
<td>41.3%</td>
<td></td>
<td>Odds ratio 1.24 (0.54 to 2.80)</td>
<td>0.61</td>
<td>1.06 (0.36 to 3.02)</td>
<td>0.92</td>
</tr>
<tr>
<td>90-day all-cause mortality</td>
<td></td>
<td>45.7%</td>
<td></td>
<td>Odds ratio 1.32 (0.59 to 2.93)</td>
<td>0.50</td>
<td>1.32 (0.55 to 3.13)</td>
<td>0.53</td>
</tr>
</tbody>
</table>

SD = standardized difference.

Values expressed as percentage or median (interquartile range) calculated after handling missing data by multiple imputations, unless indicated otherwise.

* Prespecified as the primary efficacy outcome measure.

† Calculated from nonparametric ANCOVA on rank-transformed data, adjusted for admission NIHSS score; 95% CI was calculated using the bootstrap method (2000 bootstrap samples).

‡ Adjusted for age, admission NIHSS score, diabetes, and time from symptom onset to groin puncture.
References


5. Dargazanli C, Consoli A, Barral M, Labreuche J, Redjem H, Gonesse Hospital; Paul-Emile Labeyrie, Hospices Civils de Lyon; Geomecse Rodech, Foch Hospital; Delphine Lopez, Foch Hospital; Michel Piotin, Rothschild Foundation; Raphael Blanc, Rothschild Foundation; Hocine Redjem, Rothschild Foundation; Stanislas Smajda, Rothschild Foundation; Jean-Philippe Desilles, Rothschild Foundation; Gabrielle Ciccio, Rothschild Foundation; Staviosla Smaida, Rothschild Foundation; Candece Sabben, Rothschild Foundation; Guillaume Taylor, Rothschild Foundation; Malek Ben Maacha, Rothschild Foundation; Fernando Pico, Versailles Hospital; Raja Rakotoharinandrasana, Dreux Hospital; Philippe Tassan, Poissy Hospital; Roxanna Poll, Pontoise Hospital; Haja Rakotoharinandrasana, Dreux Hospital; Oguzhan Coskun, Foch Hospital; Georges Rodesch, Foch Hospital; Philippe Tassan, Poissy Hospital; Roxanna Poll, Pontoise Hospital; Viena Vallet, Vienne Hospital.

B. Gory et al.
B. Gory et al.

Disclosures
Dr. Mazighi has been a consultant for Medtronic. Dr. Turjman has been a consultant for Codman, Balt, and Medtronic.

Author Contributions
Conception and design: Gory, Lapergue. Acquisition of data: Gory, Mazighi, Blanc, Piotin, Turjman, Lapergue. Analysis and interpretation of data: Gory, Mazighi, Blanc, Piotin, Turjman, Lapergue. Drafting the article: Gory. Critically revising the article: Gory, Mazighi, Lapergue. Reviewed submitted version of manuscript: Gory, Mazighi, Blanc, Piotin, Turjman, Lapergue. Approved the final version of the manuscript on behalf of all authors: Gory. Statistical analysis: Labreuche. Study supervision: Gory, Lapergue.

Correspondence
Benjamin Gory: CHRU Nancy, Hôpital Central, Nancy, France. b.gory@chru-nancy.fr.